Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's disease
Biotech
Sanofi signs 2nd biotech deal of the day
Sanofi is paying Adel $80 million in cash, with the total deal potentially reaching up to $1.04 billion, plus royalties.
Gabrielle Masson
Dec 15, 2025 5:50pm
Fierce Pharma
With site 'irregularities,' BMS delays key Cobenfy readout
Dec 3, 2025 10:14am
Fierce Pharma
Novo reports 2 trial failures for GLP-1 in Alzheimer's disease
Nov 24, 2025 11:41am
J&J's anti-tau antibody posdinemab flops in phase 2
Nov 24, 2025 9:40am
Labcorp to carry Roche's FDA-cleared Alzheimer's blood test
Oct 24, 2025 8:45am
2 European biotechs link to tackle neurodegenerative diseases
Oct 20, 2025 8:20am
